<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948528</url>
  </required_header>
  <id_info>
    <org_study_id>AnchorDx BC006</org_study_id>
    <nct_id>NCT04948528</nct_id>
  </id_info>
  <brief_title>Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma Detection</brief_title>
  <official_title>Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnchorDx Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AnchorDx Medical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to determine the efficacy (sensitivity and specificity) of Anchordx's urine&#xD;
      DNA methylation/somatic mutation assay for detecting upper tract urothelial carcinoma&#xD;
      compared to pathology in patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study that involves 8 centers in China and 490 participants. The test&#xD;
      analyzes the DNA methylation/somatic mutation profiles of urothelial cancer-specific&#xD;
      biomarkers non-invasively using urine specimens collected before invasive&#xD;
      diagnosis/treatment. The efficacy (sensitivity and specificity) of the assay for detection of&#xD;
      upper tract urothelial carcinoma is evaluated in comparison to pathology or cystoscopy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of urine DNA methylation/somatic mutation test</measure>
    <time_frame>1 Year</time_frame>
    <description>Sensitivity and specificity of urine DNA methylation/somatic mutation test (the proportion of pathology that are correctly identified as such by pathology)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">490</enrollment>
  <condition>Upper Tract Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Case group:</arm_group_label>
    <description>All suspected upper tract urothelial carcinoma participants will be assigned to case group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>All suspected upper tract urothelial benign participants such as ureteral/renal calculi, ureteral stricture, upper urinary tract polyps, pyelonephritis, urinary tuberculosis will be assigned to control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Comparator: Surgery Pathology or Cystoscopy</intervention_name>
    <description>Case group will be followed up with surgery pathology or cystoscopy.</description>
    <arm_group_label>Case group:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Comparator: Clinical Diagnosis</intervention_name>
    <description>Control group will be diagnosed in clinical.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      First void and non-first-void urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        suspected upper tract urothelial carcinoma patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Case group:&#xD;
&#xD;
          -  1.Any male or female patient aged 18 or older.&#xD;
&#xD;
          -  2.Able to provide urine specimen (100ml for both first void and non-first-void urine)&#xD;
             before treatments.&#xD;
&#xD;
          -  3.Diagnosed with incident upper tract urothelial carcinoma (including renal pelvis&#xD;
             carcinoma and ureteral carcinoma) by surgery.&#xD;
&#xD;
          -  4.Able to provide legally effective informed consent.&#xD;
&#xD;
        Control group:&#xD;
&#xD;
          -  1.Any male or female patient aged 18 or older.&#xD;
&#xD;
          -  2.Able to provide urine specimen (100ml for both first void and non-first-void urine)&#xD;
             before treatments.&#xD;
&#xD;
          -  3.Diagnosed with urinary disease such as ureteral/renal calculi, ureteral stricture,&#xD;
             upper urinary tract polyps, pyelonephritis, urinary tuberculosis.&#xD;
&#xD;
          -  4.Able to provide legally effective informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Patients had been diagnosed with cancer history.&#xD;
&#xD;
          -  2.Patients diagnosed with cancers unmatched with inclusion criteria cancers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian HUANG, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xu Chen, MD</last_name>
    <phone>+86-13430306339</phone>
    <email>chenx457@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xia Li</last_name>
    <phone>+86-15902059556</phone>
    <email>xia_li@anchordx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu CHEN, MD</last_name>
      <phone>+86-13430306339</phone>
      <email>chenx457@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jian HUANG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liqun ZHOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xu CHEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanqing GONG, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>June 27, 2021</last_update_submitted>
  <last_update_submitted_qc>June 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>upper tract urothelial carcinoma</keyword>
  <keyword>urine</keyword>
  <keyword>DNA methylation</keyword>
  <keyword>somatic mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

